Introduction: COVID-19 is a disease caused by a new beta coronavirus (SARS-CoV-2), whose spectrum includes severe cases with pneumonia and systemic complications that occur as a consequence of an exaggerated release of inflammatory mediators known as "cytokine storm". In this type of patients, blood purification therapies, including hemoadsorption and plasma therapy, could have an important clinical benefit and avoid complications such as multiple organ dysfunction and death. Objective: to review all available literature about blood purification therapies and their benefits in patients with COVID-19. Materials and methods: a literature search was conducted in the ClinicalKey, Embase, PubMed and Ovid databases using the terms "COVID-19", "SARS-CoV-2", "Tormenta de citoquinas", "terapias de purificación sanguínea", "sepsis", "hemoadsorción" and "CytoSorb". Results: 246 references were found and after applying filters, 61 publications with relevant content for the present review were selected. Conclusion: taking into account the great scientific evidence in the management of the cytokine storm in other scenarios, blood purification therapies, including diffusive, convective, hemoadsorption and plasma therapy techniques, could be very promising treatment tools for patients with COVID-19.